• Home
  • Study Details
By physician referral or invitation only

ARAR2331: Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)

Pleuropulmonary Blastoma (PPB) is a rare lung tumor in young children that can grow in stages from less serious (Type I) to more dangerous (Type III). This study will test how well a drug combo: vincristine, topotecan, and cyclophosphamide (VTC) works for serious types (Type II and III) and help decide which patients with less serious tumors (Type I and Type Ir (regressed) PPB ) need chemotherapy after surgery. Researchers will also study the biology of the tumor to learn more about it.

Age & Gender

  • 0 years ~ 21 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung, Pediatric Cancers)
Rare Diseases

IRB Number

25-1874

ClinicalTrials.gov

NCT06647953

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research